Columbus Circle Investors’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-199,874
Closed -$3.01M 210
2017
Q3
$3.01M Buy
199,874
+108,252
+118% +$1.43M 0.05% 200
2017
Q2
$923K Sell
91,622
-68,895
-43% -$554K 0.02% 228
2017
Q1
$1.14M Sell
160,517
-74,974
-32% -$474K 0.02% 244
2016
Q4
$1.17M Sell
235,491
-95,505
-29% -$661K 0.02% 234
2016
Q3
$2.45M Buy
330,996
+111,010
+50% +$750K 0.03% 227
2016
Q2
$1.2M Buy
219,986
+56,653
+35% +$396K 0.01% 225
2016
Q1
$1.38M Sell
163,333
-64,556
-28% -$457K 0.01% 231
2015
Q4
$2.21M Buy
227,889
+125,574
+123% +$1.13M 0.02% 240
2015
Q3
$1.43M Sell
102,315
-11,388
-10% -$179K 0.01% 239
2015
Q2
$1.61M Sell
113,703
-147,242
-56% -$1.77M 0.01% 243
2015
Q1
$2.84M Buy
260,945
+82,344
+46% +$726K 0.02% 244
2014
Q4
$1.49M Buy
178,601
+140,585
+370% +$965K 0.01% 249
2014
Q3
$226K Buy
+38,016
New +$199K ﹤0.01% 260

Other funds holding FOLD

Columbus Circle Investors's FOLD Position: Q4 2017 in Review

Columbus Circle Investors sold out of Amicus Therapeutics (FOLD) in Q4 2017, closing a stake of 199,874 shares — an estimated $3.01M sold.

Columbus Circle Investors first reported a position in FOLD in Q3 2014 and held it in 13 quarters. The position peaked at $3.01M in Q3 2017. 185 funds tracked by Wall St. Rank hold FOLD as of Q4 2017.

  • Columbus Circle Investors reported no remaining Amicus Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Columbus Circle Investors sold 199,874 Amicus Therapeutics shares in Q4 2017, an estimated $3.01M.
  • Columbus Circle Investors first reported a position in Amicus Therapeutics in Q3 2014 and held it in 13 quarters.
  • Columbus Circle Investors's Amicus Therapeutics position peaked at $3.01M in Q3 2017.
  • 185 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2017.

Based on Columbus Circle Investors's 13F filing for Q4 2017, filed 2 Feb 2018.